D.E. Shaw & Co
ELTX icon

D.E. Shaw & Co’s Elicio Therapeutics ELTX Stock Holding History

D.E. Shaw & Co’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,601
Closed -$161K – 5431
2022
Q1 		$161K Sell
7,601
-1,713
-18% -$38.7K ﹤0.01% 4924
2021
Q4 		$270K Buy
+9,314
New +$471K ﹤0.01% 4727

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

D.E. Shaw & Co's ELTX Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Elicio Therapeutics (ELTX) in Q2 2022, closing a stake of 7,601 shares — an estimated $161K sold.

D.E. Shaw & Co first reported a position in ELTX in Q4 2021 and held it in 2 quarters. The position peaked at $270K in Q4 2021. 43 funds tracked by Wall St. Rank hold ELTX as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Elicio Therapeutics position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 7,601 Elicio Therapeutics shares in Q2 2022, an estimated $161K.
  • D.E. Shaw & Co first reported a position in Elicio Therapeutics in Q4 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Elicio Therapeutics position peaked at $270K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.